December 1, 2021 -- Immunicum and PCI Biotech will jointly research introducing tumor-independent immune targets into the tumor microenvironment with vaccination or adoptive immunotherapies as a possibility of overcoming current hurdles in cancer immunotherapy.
The tumor independent-antigen concept developed by Immunicum could benefit from PCI Biotech's antigen-delivery technologies based on photochemical internalization (PCI), according to the two companies. Following the initial success of in vitro results, the companies will evaluate the novel therapeutic concept in animal models.
Immunicum is focused on hard-to-treat established tumors and preventing cancer recurrence. PCI Biotech specializes in the development and commercialization of novel therapies for the treatment of cancer through its innovative PCI technology platform.
No financial details of the collaboration declarations were disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
